BridgeBio reports $154.2M Q4 revenue and secures three Phase III successes
BridgeBio posted $154.2 million Q4 net revenue and $502.1 million full year results, powered by $146.0 million Q4 and $362.4 million product sales. It reported three Phase III wins: PROPEL 3 infigratinib improved AHV by 2.10 cm/year (p<0.0001), BBP-418 FORTIFY added 2.6-point NSAD gain, and encaleret CALIBRATE delivered positive toplines ahead of 1H/2H 2026 NDA submissions.
1. Robust Fourth Quarter and Full Year Revenues
BridgeBio posted $154.2 million in net revenue for Q4 2025 and $502.1 million for the full year, with net product sales of $146.0 million in Q4 and $362.4 million in annual product revenue.
2. Three Positive Phase III Readouts
Three Phase III trials delivered positive results: infigratinib PROPEL 3 showed a 2.10 cm/year AHV increase over placebo (p<0.0001), BBP-418 FORTIFY achieved a 2.6-point NSAD improvement at 12 months, and encaleret CALIBRATE recorded positive toplines.
3. Strong Commercial Growth and Cash Position
Attruby prescriptions reached 7,804 from 1,856 prescribers as of February 20, 2026; the company held $587.5 million in cash and equivalents and issued $632.5 million of convertible notes due 2033 to fund commercial and pipeline operations.